PharmacoEconomics - Modern pharmacoeconomics and pharmacoepidemiology (E-Journal) / ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология
Not a member yet
430 research outputs found
Sort by
Фармакоэкономическое исследование применения препарата Везомни (тамсулозин с контролируемым высвобождением + солифенацин) при нарушениях мочеиспускания, связанных с доброкачественной гиперплазией предстательной железы
Get PDFThe aim of the current study is pharmacoeconomic evaluation of using combined drug Vesomni (controlled release tablets tamsulosin 0.4 mg + solifenacin 6 mg) for treatment of patients with storage symptoms associated with benign prostatic hyperplasia, who do not respond to first line tamsulosin therapy.Materials and methods. We consider three therapy options: 1) combined drug Vesomni; 2) combination of tamsulosin (modified release capsules 0.4 mg) and solifenacin (5 mg); 3) combination of tamsulosin (controlled release tablets 0.4 mg) and solifenacin (5 mg). These options are evaluated with cost minimization and budget impact analysis.Results. We found that approx. 250,000 patients in Russia need combined tamsulosin and solifenacin therapy, including 35,400 patients eligible for government reimbursement. Using combined drug is cost saving alternative that annually requires 22,000 rubles per patient, which is 2,000 rubles less than second best option. The overall healthcare annual expenses of using combined drug are 5,7 billion rubles (500 million rubles less than for second best option), and government reimbursement costs are 606 million rubles (74 million less than for second best option).Conclusion. Using combined drug Vesomni for treatment of patients with storage symptoms associated with benign prostatic hyperplasia is cost saving alternative compared to combination of monotheraphy regimens
ABC-, VEN- и частотный анализ терапии фибрилляции предсердий в условиях «типичной практики»
Get PDFAtrial fibrillation is a serious social and health problems, the most common arrhythmia in practice, leading to an increased risk of death, stroke, heart failure. The results of pharmacoeconomical studies allow to evaluate the quality of drug therapy for atrial fibrillation, find rational drug usage and identify ways to optimize the consumption of medications. The objective of investigation is to hold ABC-, VENand frequency analysis of atrial fibrillation in out-patients to assess their compliance with national and international recommendations. Materials and methods. To analyze the treatment of atrial fibrillation 98 outpatients with atrial fibrillation were randomly selected. Every patient appealed to the reception to the physician at least twice in 2013. The data was recorded in a special card, and then analyzed using ABC-, VENand frequency analysis. Results. For the treatment of patients with different forms of atrial fibrillation has been used 114 types of drugs to the INN. Patients received from 3 to 12 drugs. For the treatment of patient with atrial fibrillation it spends an average of 11245.2 rubles per patient, for the treatment of heart disease it spends 8379.51 rubles., that is about 74.5%. The study found that received data is satisfied modern recommendations. The results of frequency analysis showed that the most prescribed drugs are medications with proven efficacy to the quality and duration of life. Conclusions. Data analysis revealed that the percentage volume of drugs between the groups as a whole corresponds to the recommended distribution of drugs
Сравнительный клинико-экономический анализ интенсификации терапии базальным инсулином или дапаглифлозином у пациентов с неконтролируемым сахарным диабетом 2-го типа
Get PDFObjective. Determine if dapagliflozin use is pharmacoeconomically reasonable option for patients with inadequate glycemic control compared with basal insulin.Materials and Methods. The study was conducted according to standard pharmacoeconomic methods: cost-utility analysis (CUA), budget impact analysis (BIA).Results. The use of dapagliflozin as an alternative to basal insulin can reduce health system costs, improves the quality of life of patients, adding 0.73 QALY per patient. Modelling suggests that dapagliflozin introduction could delay the start of insulin treatment by an average of 6.5 years that in turn will allow achieving cost savings and improving the quality of life of patients.Conclusions. Dapagliflozin therapy is the preferred alternative to basal insulins, due to lower costs and improvement in the quality of life of patients.Цель – определить, является ли выбор дапаглифлозина фармакоэкономически обоснованным при включении его в терапию у пациентов с недостаточным гликемическим контролем в сравнении с базальными инсулинами.Материалы и методы. Исследование проводилось по стандартным фармакоэкономическим методикам анализа полезности затрат (CUA), оценки влияния на бюджет.Результаты. Применение дапаглифлозина в качестве альтернативного базальному инсулину препарата при интенсификации терапии СД 2-го типа позволяет сократить затраты системы здравоохранения, а также повышает качество жизни пациентов, добавляя 0,73 QALY в расчете на одного пациента и позволяет отложить старт инсулинотерапии в среднем на 6,5 лет, что позволит достичь экономии бюджетных средств и улучшить качество жизни пациентов.Выводы. Терапия дапаглифлозином является предпочтительной альтернативой в сравнении с использованием базальных инсулинов, поскольку сопровождается наименьшими затратами и позволяет улучшить качество жизни пациентов
Влияние на бюджет добавления перампанела к терапии больных эпилепсией в возрасте 12 лет и старше при парциальных приступах с вторичной генерализацией и без нее и при первично-генерализованных тонико-клонических приступах в условиях Российской Федерации
Get PDFObjectives. To assess the incremental budget impact (BI) of using of utilizing perampanel to treat partial-onset seizures (POS) and primary generalized tonic-clonic seizures (PGTCS) in patients who are 12 years of age and older in Russia.Methods. The budget impact was estimated by comparing two different scenarios: Cost of POS & PGTCS without Perampanel and Cost of POS & PGTCS with Perampanel (Perampanel Adoption). In the latter scenario, market share of perampanel was assumed to increase every year for up to five years. The model was developed from a payer perspective with a time horizon of five years. Direct costs included drugs and medical resources (hospitalization, emergency care costs, visits to physician). BI was calculated as the difference in costs between Perampanel Adoption scenario and the cost without Perampanel.Results. In Russia, approximately 125,499 patients who are at least 12 years old are treated for refractory POS & PGTCS each year. The market share of perampanel in the perampanel adoption scenario from year 1 to year 5 was 0.1%, 0.5%, 1.0%, 2.0% and 3.0%, respectively. During the same period, the adoption of perampanel is projected to increase drug costs (in millions) by RUB15.2 (1.2%), RUB76.1 (6.2%), RUB152.4 (12.3%), RUB305.4 (24.7%), and RUB459.0 (37.0%), respectively. A significant portion of the 5-year cumulative increase in drug costs (RUB 1,008 million) will be offset by a decrease in non-drug medical resources (-RUB152.7 million). The cumulative budget impact from perampanel adoption for the first five years is projected to be RUB855 million (0.7%), with an additional 231 patients gaining seizure freedom over a period of 5 years from the adoption of perampanel.Conclusion. Perampanel should be considered as an alternative alongside current antiepileptic drugs in patients with symptoms refractory to prior antiepileptic treatments
Модели анализа включений лекарственных средств в ограничительные перечни (на примере ЖНВЛП) 2016 г.
Get PDFBackground: In 2014 we firstly analyzed the formalized system (points and expert opinions) of drug inclusion and exclusion into the reimbursement lists in Russian Federation. The liner mathematical model of decision making was developed and adopted.Aim. Update the existing model using the results of reimbursement procedures acting from 2106.Material and methods. The linear models developed and adopted in 2014 were used. In 2015 we included data on 141 drug dossiers. We analyzed the decision of the expert body, chief Ministry of Health expert and the final committee decision.Results. 43 new drugs were included into the reimbursement lists acting from 2016. The model of expert body decision had an error 7,09% (12,4% in 2014). The model of chief Ministry of Health expert decision had an error – 7% (10% in 2014). The above mentioned experts became more experienced in the formalized procedure of decision making. The model of final decision had an error about 42% (35% in 2014). Conclusion. Linear models are working tools for modelling reimbursement system decisions. At the mean time the existing system of decision making needs more formalization
Фармакоэкономическое обоснование применения генно-инженерных биологических препаратов в амбулаторных условиях
Get PDFМониторинг потребительского отношения населения к лекарственным средствам
Get PDFObjective. Comparative analysis and monitoring of the population’s attitude to medicines through an assessment of their consumer qualities by visitors of pharmacies.Materials and Methods. Conducted two sociological survey thru the original questionnaires in 2002 and 2015 among pharmacy customers. Each survey included 380 respondents living in the cities of Central Russia. During the interviews, respondents were asked, among other things evaluate the 13 influencing their choice of consumer qualities of medicines. Six of these qualities characterize the pharmaceutical features and merchandising options are seven parameters of medicines. Statistical analysis used a set of indicators of variation statistics, ranking, rank correlation.Results. Ratings of consumer qualities of medicines are obtained for the studied years and changes in the whole period of monitoring. We have identified the priority characteristics of medicines which are essential for consumers, in particular: efficiency, clear information on the package, low cost, minor side effects, convenient way to receive.Conclusion. The revealed features of consumer attitudes to medicines should be taken into account pharmaceutical workers in information and consultative dealing with pharmacies visitors
Фармакоэкономический анализ терапии пациентов с хронической обструктивной болезнью легких в стационарных условиях
Get PDFObjective. To determine the priority used to vital drugs in сhronic obstructive pulmonary disease (COPD) patients in hospitals of the Kirov region.Materials and Methods. We analyzed 143 medical records of the patient, the analysis of cost of illness, ABC\ VEN — analysis.Results. The results of АВС analysis show that the percentage correlation of medicines of different groups generally corresponds to the recommended norm. The results of VEN analysis prove that the number of vital drugs is decreased while the number of second line drugs is increased.Conclusion. Most of the financial costs were for the treatment of exacerbations of COPD, the appropriate Federal clinical guidelines, simultaneously, there is an active assignment of the second line drugs. Reducing their use and rational therapy of acute conditions will enable competently reallocate financial resources in favour of vital drugs to increase the effectiveness of treatment and reduce the cost of inpatient care
Подходы к понятиям продуктивности, результативности и эффективности в сфере научных исследований и разработок
Get PDFThe article analyzes the Russian and foreign approaches to the disclosure of the terms "effectiveness", "productivity", "efficiency". Identified, analyzed concepts are closely related, however, there is currently no generally accepted formulations, which can lead to misunderstandings, errors in managerial decision-making needs to be redressed. Recommendations on fixing these concepts in normative legal and methodical documents regulating, in particular the development of science, and establishing indicators of results, efficiency and effectiveness of research organizations. В статье проанализированы российские и зарубежные подходы к раскрытию понятий «результативность», «продуктивность», «эффективность». Выявлено, что анализируемые понятия тесно взаимосвязаны, однако в настоящее время не имеют строгих общепринятых формулировок, что может привести к разночтениям, ошибкам в принятии управленческих решений и требует их устранения. Приведены рекомендации по закреплению этих понятий в нормативных правовых и методических документах, регулирующих, в частности, вопросы развития сферы науки и устанавливающих показатели результатов, результативности и эффективности деятельности научных организаций